Answers are grounded in this paper and cite their sources.
Epstein-Barr virus (EBV) is a herpesvirus that is transmitted person-to-person and is rapidly acquired during childhood and adolescence. EBV establishes a life-long infection and is associated with symptomatic infectious mononucleosis (IM) as well as longer-term sequelae such as certain cancers (Hodgkin’s Lymphoma, Nasopharyngeal Carcinoma, Burkitt’s Lymphoma) and the autoimmune disease multiple sclerosis. The risk for these outcomes tend to differ by the age of EBV infection. There are several ongoing efforts to develop prophylactic and therapeutic interventions against EBV in order to reduce the risk of these long-term sequelae. Data on age-specific seroprevalence of EBV as well as factors associated with seropositivity could be helpful to guide the development and evaluation of these interventions. A systematic literature review of global EBV seroprevalence was conducted among English language literature published between January 2013–April 2024 reporting EBV serostatus in healthy individuals aged 1–25-years. This review identified 18 studies from 10 countries with relevant EBV serostatus information. Most studies were from the US, UK and Europe. Nationally representative, age-specific EBV seroprevalence data were limited to studies conducted in the US and UK. EBV seroprevalence increased by age in all countries with seroprevalence reaching > 90% by the age of 20. Several demographic (older age, non-white race/ethnicity, lower education, lower income) and behavioral (sexual activity, smoking) characteristics were associated with a higher seroprevalence. Heterogeneity in study design, populations, statistical analyses, and laboratory testing was observed, which limited cross-section comparisons and the generation of summary estimates of seroprevalence. This systematic review of studies of EBV seroprevalence observed that EBV is acquired rapidly during children and adolescence with a majority of individuals seropositive by young adulthood. The majority of EBV seroprevalence estimates summarized in this review were derived from population-based studies conducted in the US and UK. Additional similar studies are therefore needed across other geographies to better understand the global burden of EBV infection. Information provided in this review are helpful in guiding decisions on population selection for clinical trials evaluating preventative and/or therapeutic interventions of EBV.
No takes yet. Share an insight, caveat, or question.
Nahhas et al. (2026) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: